XBiotech Inc. (NASDAQ:XBIT) Sees Large Growth in Short Interest

XBiotech Inc. (NASDAQ:XBIT) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 907,400 shares, a growth of 15.2% from the January 15th total of 787,900 shares. Currently, 4.7% of the company’s shares are sold short. Based on an average daily trading volume, of 71,300 shares, the short-interest ratio is presently 12.7 days.

Hedge Funds Weigh In On XBiotech

Large investors have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of XBiotech by 2.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,770 shares of the biopharmaceutical company’s stock worth $1,962,000 after purchasing an additional 5,500 shares in the last quarter. State Street Corp raised its position in XBiotech by 10.7% in the 3rd quarter. State Street Corp now owns 224,595 shares of the biopharmaceutical company’s stock valued at $1,736,000 after buying an additional 21,752 shares during the last quarter. Barclays PLC increased its position in shares of XBiotech by 247.4% during the 3rd quarter. Barclays PLC now owns 26,343 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 18,761 shares during the last quarter. Geode Capital Management LLC increased its position in shares of XBiotech by 5.1% during the 3rd quarter. Geode Capital Management LLC now owns 452,264 shares of the biopharmaceutical company’s stock valued at $3,496,000 after purchasing an additional 22,059 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in XBiotech in the 3rd quarter worth about $86,000. 55.70% of the stock is currently owned by institutional investors.

XBiotech Trading Up 1.9 %

Shares of XBIT opened at $3.27 on Friday. XBiotech has a 12-month low of $3.05 and a 12-month high of $9.96. The business’s fifty day moving average is $4.36 and its 200 day moving average is $6.04.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.